Investor Presentaiton

| SARTATE™M Clinical trials CL04 SARTATE™M CLO4: 67CU-SARTATE™M Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma 64Cu/67 CU SARTATET Phase I/lla trial in high-risk neuroblastoma in the US with up to 34 patients Trial design Multi-centre, dose-escalation, open label, non-randomised, theranostic clinical trial Status Cohort 1 complete, no safety issues Cohort 2 in the therapy trial in progress Neuroblastoma is one of the most aggressive childhood cancers 800 new cases each year in the US and the most common cancer in infants Neuroblastoma accounts for approximately 13% of paediatric cancer mortalities Approximately 84% of neuroblastomas express SSTR2 DISC DISCO: Diagnostic Imaging Study of Copper-64 SARTATE using PET on patients with known or suspected NETS • Assesses the performance of imaging agent 64CU SARTATE™M in participants with known or suspected gastroenteropancreatic NETs as a potential new way to help diagnose and manage NETS Aims to capture and highlight the significant advantages of the longer half-life (12.7 hours) of copper-64, related to imaging and product supply which are relevant to Clarity's entire pipeline of products in development Trial design ° • Phase II multi-centre, single arm, non-randomised, blinded-review study in up to 63 participants Compares diagnostic performance of 64 CU SARTATETM at 4 and 20 hours to the current standard of care, 68 Ga DOTATATE, at 1 hour Status Currently recruiting at four sites with 64CU SARTATEM manufactured centrally in Australia CLARITY 2014 ME CL04 ClinicalTrials.gov identifier: NCT 04023331 DISCO ClinicalTrials.gov identifier: NCT 04438304 21

View entire presentation